Stockscreener 앱 받기
0.157
4.96%
-0.0082
전일 마감가:
$0.1652
열려 있는:
$0.1675
하루 거래량:
38.27M
Relative Volume:
3.24
시가총액:
$76.75M
수익:
$55.54M
순이익/손실:
$-180.40M
주가수익비율:
-0.1993
EPS:
-0.7877
순현금흐름:
$-170.32M
1주 성능:
-6.55%
1개월 성능:
-28.64%
6개월 성능:
-95.14%
1년 성능:
-87.92%
1일 변동 폭
$0.151
$0.1712
1주일 범위
$0.151
$0.1813
52주 변동 폭
$0.14
$3.87
Gossamer Bio Inc Stock (GOSS) Company Profile
명칭
Gossamer Bio Inc
전화
(858) 684-1300
주소
3115 MERRYFIELD ROW, SAN DIEGO, CA
Compare GOSS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
0.157 | 76.75M | 55.54M | -180.40M | -170.32M | -0.7877 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2026-02-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2026-02-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-02-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-09-10 | 업그레이드 | UBS | Neutral → Buy |
| 2025-07-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-05 | 재개 | Wedbush | Outperform |
| 2023-07-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-03-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | 개시 | Guggenheim | Neutral |
| 2022-12-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-12-07 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-12-07 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-09-21 | 개시 | JP Morgan | Neutral |
| 2022-09-19 | 개시 | Wedbush | Outperform |
| 2022-04-18 | 개시 | Raymond James | Outperform |
| 2022-04-06 | 개시 | UBS | Buy |
| 2022-01-10 | 업그레이드 | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-09-21 | 재개 | Piper Sandler | Overweight |
| 2020-06-29 | 개시 | H.C. Wainwright | Buy |
| 2020-04-22 | 개시 | Piper Sandler | Overweight |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-30 | 개시 | Berenberg | Buy |
| 2019-03-05 | 개시 | Barclays | Overweight |
| 2019-03-05 | 개시 | BofA/Merrill | Buy |
| 2019-03-05 | 개시 | Evercore ISI | Outperform |
| 2019-03-05 | 개시 | SVB Leerink | Outperform |
모두보기
Gossamer Bio Inc 주식(GOSS)의 최신 뉴스
H.C. Wainwright cuts Gossamer Bio stock price target to $2 on debt exchange By Investing.com - Investing.com Australia
H.C. Wainwright cuts Gossamer Bio stock price target to $2 on debt exchange - Investing.com Nigeria
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
Gossamer Bio Price Target Cut to $2.00/Share From $5.00 by HC Wainwright & Co. - Moomoo
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
GOSS Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Gro - The National Law Review
Gossamer Bio, Inc. Actuals & Estimates (NASDAQ:GOSS) - TradingView
Gossamer Bio Inc (GOSS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Gossamer Bio, Inc. (GOSS) And Encourages Investors to Connect - ACCESS Newswire
GOSS News | GOSSAMER BIO INC (NASDAQ:GOSS) - ChartMill
Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Gossamer Bio opens the week with chart pressure, shares trade near Nasdaq penny range - AD HOC NEWS
Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Gossamer Bio, Inc. (GOSS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Gossamer Bio Inc (NASDAQ: GOSS) Share Price, GOSS Stock News, GOSS Share Price & Updates - Kalkine
Gossamer Bio (GOSS) Stock Faces Mixed Analyst Target Changes On Funding Risk - Yahoo Finance
Gossamer Bio Insiders Are Down US$45k But Regain Some Losses - simplywall.st
Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gossamer Bio Inc (GOSS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
683 Capital Management, LLC Acquires Significant Stake in Gossamer Bio Inc - GuruFocus
Gossamer Bio Inc (GOSS) Q1 2026 Earnings Call Highlights: Strategic Debt Reduction and ... By GuruFocus - Investing.com Canada
Gossamer Bio Inc (GOSS) Q1 2026 Earnings Call Highlights: Strate - GuruFocus
Gossamer Bio Inc. has officially announced the final tender results for its exchange offer and consent solicitation regarding its outstanding convertible notes. - Bitget
GOSS: Gossamer Bio Concludes Exchange Offer for Convertible Seni - GuruFocus
Gossamer Bio Inc (GOSS) Institutional Confidence - TradingKey
Gossamer Bio Inc (GOSS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Gossamer Bio completes exchange offer for convertible notes By Investing.com - Investing.com South Africa
Gossamer Bio completes exchange offer for convertible notes - Investing.com
Gossamer Bio Inc (GOSS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gossamer Bio final tender results: $72M new notes, 317.6M shares available; $18.95M old notes remain - TradingView
Gossamer Bio (NASDAQ: GOSS) swaps most 2027 converts into 2030 debt and equity - Stock Titan
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - Business Wire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Context Capital Management, LLC Acquires Significant Stake in Go - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Investors to Inquire about Securities Investigation - ACCESS Newswire
D. E. Shaw (GOSS) discloses 9.5% stake after major exchange offer - Stock Titan
David E. Shaw Discloses Investment at Gossamer Bio with 9.5% Stake - TradingView
[SCHEDULE 13G] Gossamer Bio, Inc. Passive Investment Disclosure (>5%) - Stock Titan
683 Capital reports 49.87M-share position in Gossamer Bio (NASDAQ: GOSS) - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gossamer Bio, Inc. (GOSS) And Encourages Investors to Reach Out - ACCESS Newswire
2026-06-11 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gossamer Bio, Inc. (GOSS) And Encourages Investors to Reach Out | NDAQ:GOSS | Press Release - Stockhouse
Massive recapitalization at Gossamer Bio (NASDAQ: GOSS) could give noteholders majority control - Stock Titan
Context Capital (GOSS) discloses 48.8M-share, 9.9% stake in Gossamer Bio - Stock Titan
Gossamer Bio (NASDAQ: GOSS) awards 115K stock options to director - Stock Titan
Gossamer Bio (GOSS) director Skye Drynan awarded 115,000 stock options at $0.178 - Stock Titan
Gossamer Bio (GOSS) director receives 115,000 stock options as board compensation grant - Stock Titan
Director at Gossamer Bio (NASDAQ: GOSS) receives 115K stock options - Stock Titan
Gossamer Bio (GOSS) director awarded 115,000 stock options as compensation - Stock Titan
Gossamer Bio (NASDAQ: GOSS) awards director 115,000 stock options - Stock Titan
Gossamer Bio, Inc. 8-K Filing June 2026: Annual Meeting Results and Company Information - Minichart
Gossamer Bio Inc (GOSS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.36%
자본화:
|
볼륨(24시간):